Clinical Outcomes and Prognosis Analysis of Younger Bladder Cancer Patients

Curr Oncol. 2022 Jan 28;29(2):578-588. doi: 10.3390/curroncol29020052.

Abstract

Background: Generally, little is known about prognostic factors in bladder cancer patients under 40 years of age. We therefore performed a retrospective study to identify prognostic factors in these younger bladder cancer patients.

Methods: We collected clinicopathological data on bladder cancer patients ≤40 years old diagnosed between 1975 and 2018 from the Surveillance, Epidemiology, and End Results (SEER) database. Survival curves were generated using the Kaplan-Meier method, and the differences between groups were analyzed using the log-rank test. Univariate and multivariate Cox hazards regression analyses were performed to define hazard ratios (HRs) for cancer-specific survival (CSS).

Results: There were statistical differences in race, histological type, cancer stage, tumor size, and surgery treatment groups between overall survival and CSS. Only tumor size and cancer stage were significant independent prognostic risk factors in younger bladder cancer patients for the prediction of CSS.

Conclusion: Tumors greater than 30 mm in size and a more advanced stage of bladder cancer were indicative of a poor prognosis in bladder cancer patients ≤40 years old, and long-term follow-up is suggested.

Keywords: 40 years; bladder cancer; prognostic factors; survival.

MeSH terms

  • Adult
  • Humans
  • Prognosis
  • Retrospective Studies
  • SEER Program
  • Survival Rate
  • Urinary Bladder Neoplasms* / therapy